Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Heritage Bio Labs

Research Library

Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.

Browse by productGeneral topics

Find articles

Matching articles

Showing 13–24 of 134 articles · Explore study findings

Clear search and filters

  • Explore study findings

    What AICAR did during DNA copying in esophageal cancer cells

    AICAR, also called acadesine, is a ribonucleoside rather than an amino-acid chain. Cells can convert it into a nucleotide called ZMP, which can activate an energy-sensing enzyme called AMPK.

    AICAR1 source (2026)

  • Explore study findings

    Can energy sensing change the lining of a scarred liver?

    AICAR is a different kind of molecule, a ribonucleoside that cells can turn into the nucleotide ZMP. Researchers use it to probe signaling through the energy sensor AMPK. A 2026 mouse study explored whether AICAR changed the behavior of the cells lining tiny vessels inside a scarred liver.

    AICAR1 source (2026)

  • Explore study findings

    Which form of the AMPK energy sensor responded in muscle?

    AICAR is a small ribonucleoside, and cells convert it to ZMP, a molecule that can mimic an energy-related signal. Researchers used AICAR to test which versions of the energy sensor AMPK help isolated muscle take up glucose. AMPK is made of three protein parts, each of which comes in different forms.

    AICAR1 source (2025)

  • Explore study findings

    Why AICAR changed glucose entry in cultured fat cells

    AICAR is a nonpeptide ribonucleoside that cells convert to a nucleotide called ZMP. A 2025 study used mouse-derived fat cells to ask whether AICAR could change their response to insulin through a pathway beyond the energy sensor AMPK.

    AICAR1 source (2025)

  • Explore study findings

    What the RED-CABG trial found about acadesine in heart surgery

    AICAR, also called acadesine, is a ribonucleoside. It has been studied for its effects on cellular metabolism and adenosine-related processes. For the specific question of outcomes around coronary bypass surgery, the older RED-CABG study provides randomized human evidence.

    AICAR1 source (2012)

  • Explore study findings

    What the larger AOD-9604 obesity trial found

    AOD-9604 is a modified fragment of human growth hormone studied for weight management. The older clinical evidence summarized by the FDA includes the OPTIONS trial, which tested whether the peptide produced a measurable weight difference against placebo.

    AOD-96041 source (2024)

  • Explore study findings

    What a 2026 retraction changed about kidney research

    ARA-290, also called cibinetide or pyroglutamate helix B surface peptide, is an 11-amino-acid experimental peptide designed from the shape of erythropoietin. A February 2026 journal notice changed how researchers should read one older study of the peptide in an animal model of acute kidney injury.

    ARA-2902 sources (2008, 2026)

  • Explore study findings

    Why a sarcoidosis trial photographed nerves in the cornea

    ARA-290, or cibinetide, is a synthetic 11-amino-acid peptide designed to engage a proposed tissue-protection signaling pathway. Researchers studying small nerve fibers in sarcoidosis needed a way to measure tissue changes in living people.

    ARA-2902 sources (2017, 2026)

  • Explore study findings

    What the eye study found beyond a nerve image

    ARA-290, called cibinetide in a 2020 eye study, is an 11-amino-acid peptide designed from erythropoietin. That older phase 2 pilot asked whether the peptide would affect diabetic macular edema, in which fluid accumulates in the central retina.

    ARA-2902 sources (2017, 2020)

  • Explore study findings

    What the October 2026 compounding notice covers

    BPC-157 is a synthetic 15-amino-acid peptide investigated in tissue injury models. In October 2026, the U.S. Department of Health and Human Services published a notice about an interim policy on certain peptide bulk drug substances.

    BPC-1572 sources (2026)

  • Explore study findings

    What isolated human artery rings can reveal

    BPC-157 is a synthetic chain of 15 amino acids being studied in vascular and tissue injury experiments. In May 2026, a laboratory study used pieces of human artery to ask whether BPC-157 affected vessel tension and whether the artery's inner lining contributed to the response.

    BPC-1571 source (2026)

  • Explore study findings

    Why the four arms of REDEFINE 1 mattered for cagrilintide

    Cagrilintide is an investigational long-acting amylin-based peptide. The older primary REDEFINE 1 report matters for the specific question of cagrilintide alone because the large weight-management trial included a separate cagrilintide arm alongside the fixed combination.

    Cagrilintide3 sources (2025, 2026)

Browse by product

General topics

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Library index (JSON)